Evidence map›Paper›PMID 16322063›Full record

ArticleEndocrinology2006

Angiotensin II stimulates transcription of insulin-like growth factor I receptor in vascular smooth muscle cells: role of nuclear factor-kappaB.

Yewei Ma, Liping Zhang, Tao Peng, Jizhong Cheng, Shilpa Taneja, Jiqiang Zhang, Patrice Delafontaine, Jie Du

Open access · bronzeAbstract read
In one paragraph

Article in Endocrinology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Reduced Expression of Glutathione S-TransferaseJournal of the American Society of Nephrology : JASN · 2018
    Article
  5. Effect of berberine on PPARPharmaceutical biology · 2017
    Article
  6. Insulin-Like Growth Factor-1 and Neuroinflammation.Frontiers in aging neuroscience · 2017
    Review
  7. Review
  8. Article
  9. Novel tyrosine kinase signaling pathways: implications in vascular remodeling.Current opinion in nephrology and hypertension · 2012
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Yewei MaDepartment of Medicine, One Baylor Plaza, N520, Baylor College of Medicine, Houston, Texas 77030, USA.
Liping Zhang
Tao Peng
Jizhong Cheng
Shilpa Taneja
Jiqiang Zhang
Patrice Delafontaine
Jie Du
Baylor College of Medicine · USTulane University · US

Funding

Insulin-Like Growth Factor-1and AtherosclerosisR01HL070241 · NHLBI · UNIVERSITY OF MISSOURI-COLUMBIA · PI PATRICE DELAFONTAINE · 2003 to 2026
$10.1M
Renal Inflammation: Mechanisms and ConsequencesP50DK064233 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI DU, JIE · 2003 to 2007
$5.1M
ANGIOTENSIN II, IGF-1 AND SKELETAL MUSCLE ATROPHYR01HL080682 · NHLBI · UNIVERSITY OF MISSOURI-COLUMBIA · PI DELAFONTAINE, PATRICE · 2007 to 2015
$3.3M
CHRONIC KIDNEY DISEASE ADVERSELY INFLUENCES VASCULAR FUNCTIONSR01DK095867 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI CHENG, JIZHONG · 2013 to 2017
$1.7M
IGF I, its receptor and vascular remodelingR01HL070762 · NHLBI · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI DU, JIE · 2002 to 2005
$1.4M
NHLBI NIH HHS HL 70241NHLBI NIH HHS R01 HL070241NHLBI NIH HHS R01 HL070762NHLBI NIH HHS R01 HL080682NHLBI NIH HHS R01 HL 70762NIDDK NIH HHS 1P50-DK064233NIDDK NIH HHS P50 DK064233NIDDK NIH HHS R01 DK095867
6 · The paper itself

Abstract

Increased expression of the IGF-I receptor (IGF-IR) is associated with proliferation and survival of vascular smooth muscle cells (VSMCs). In cultured VSMCs, we reported that angiotensin II (Ang II) increases transcription and expression of IGF-IR. Now, we show that mesenteric arteries of rats infused with Ang II develop thickening and increased IGF-IR expression. To determine how Ang II transcriptionally regulates IGF-IR expression in VSMCs, we generated 5'-end deletions of the IGF-IR promoter and measured Ang II-induced promoter-luciferase activity in VSMCs. Activities from these promoter sequences suggested that the Ang II-responsive region is located between -270 and -135 of the IGF-IR promoter. Using a DNase I foot printing analysis, we identified two putative nuclear factor-kappaB (NF-kappaB)-like sequences located in the same region of the IGF-IR promoter. When we mutated either of these NF-kappaB-like sites, Ang II-induced IGF-IR promoter activity decreased sharply. Electrophoretic mobility gel shift, anti-p50 of NF-kappaB supershift and chromatin immunoprecipitation assays demonstrated that both the p65 and p50 subunits of NF-kappaB will bind to this Ang II response element in the IGF-IR promoter. When we blocked the Ras/MAPK kinase 1 pathway or the inhibitory-kappaB kinase pathway, both Ang II-induced IGF-IR promoter activity and expression of IGF-IR protein significantly declined. Our results indicate that the mechanism by which Ang II stimulates IGF-IR expression in VSMCs involves NF-kappaB binding to NF-kappaB sites in the IGF-IR promoter, leading to expression of IGF-IR through both Ras/MAPK kinase 1-and inhibitory-kappaB kinase-dependent pathways. Because IGF-IR is a major factor associated with thickening of mesenteric vessels, our results provide potential therapeutic targets.

Indexed as

Transcription, GeneticAngiotensin IIAnimalsBinding SitesCells, CulturedChromatin ImmunoprecipitationDeoxyribonuclease IGene DeletionGenes, ReporterImmunohistochemistryImmunoprecipitationLuciferasesMaleMAP Kinase Signaling SystemMuscle, Smooth, VascularMyocytes, Smooth MuscleAngiotensin IIDeoxyribonuclease ILuciferasesNF-kappa BNF-kappa B p50 SubunitReceptor, IGF Type 1Transcription Factor RelA

Identifiers

PMID16322063
PMCPMC3228638
OpenAlexW1969266723

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.